Abstract 194P
Background
γδ T cells are a small subset (0.5-5%) of peripheral blood T cells playing a key role in both defense against a wide range of pathogens and anticancer immunity. In recent years, Bruton’s tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B-cell malignancies. Although primarily expressed in B-cell lineage cells, BTK expression has also been identified in other cell types. However, the role of BTK expression and the impact of BTK inhibitors on non-B cells, including γδ T cells, remain unclear.
Methods
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats using density gradient centrifugation. Selective γδ T cell expansion was achieved by adding zoledronic acid and IL-2. On day 14 of culturing, ibrutinib, acalabrutinib, or zanubrutinib were introduced. After 48 hours of co-incubation, cytokine production and γδ T cell activation were assessed. To evaluate the impact of BTK inhibitors on γδ T cell activation, HMBPP or the CLL cell line Duller was used as stimulation agents. Cytokine production was evaluated by stimulating the cells with M. tuberculosis lysate, PHA, HMBPP, or anti-CD3 [OKT3], followed by cell permeabilization, staining with specific antibodies, and analysis using flow cytometry.
Results
Ibrutinib significantly reduced the production of IFN-γ and TNF-α by γδ T cells stimulated with HMBPP, but not with Duller cells. This suggests that TCR-independent stimulation pathways, such as through the NK family of receptors, may restore cytokine production to normal levels. No significant differences were found in the production of granzyme B, IL-6, IL-9, IL-10, or IL-17a. All inhibitors reduced the early activation of γδ T cells, as indicated by decreased CD69 expression, while having no effect on late-stage activation. Interestingly, this inhibitory effect was least pronounced with ibrutinib.
Conclusions
BTK inhibitors seem to modulate γδ T cell function, with their impact being pathway-specific and potentially partially reversible depending on the type of stimulation. Moreover, newer inhibitors appear to have a lesser impact on γδ T cells, likely due to their higher specificity for BTK. From an immunotherapeutic perspective, concomitant treatment with BTK inhibitors and in vitro expanded γδ T cells could be a viable option.
Legal entity responsible for the study
Medical University of Lublin.
Funding
DKMS Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
63P - Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
Presenter: Bin Wu
Session: Poster Display session
Resources:
Abstract
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
Resources:
Abstract
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
Resources:
Abstract
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
Resources:
Abstract
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
Resources:
Abstract
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
Resources:
Abstract
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
Resources:
Abstract
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
Resources:
Abstract
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session
Resources:
Abstract